French Observatory on the Management of Cardiogenic Shock in 2016 (FRENSHOCK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02703038|
Recruitment Status : Completed
First Posted : March 9, 2016
Last Update Posted : August 15, 2019
Cardiogenic shock (CS) is defined as an organ hypoperfusion secondary to low cardiac output. Catches diagnostic management, and therapeutic monitoring of these patients remain highly variable from one center to another and even from one doctor to another within the same team. The management protocols are often not standardized or non-existent.
It appears therefore necessary to make an inventory of the management practices of the CS in France in 2016, prerequisite to a common work of standardization of practices and the creation of specialized networks to support these complex patients.
|Condition or disease|
The Observatory FRENSHOCK proposes to set up a cohort of 500 patients recruited prospectively over a period of 6 months.
Patients will be followed up at 1 month and 1 year Patients should have agreed to participate in the observatory, knowing that participation or refusal to participate will not alter the therapeutic attitude of the physician responsible for the patient. The study of phenotypic characteristics will not change the therapeutic approach of the medical teams.
|Study Type :||Observational|
|Actual Enrollment :||777 participants|
|Official Title:||French Observatory on the Management of Cardiogenic Shock in 2016|
|Actual Study Start Date :||April 2016|
|Actual Primary Completion Date :||July 2018|
|Actual Study Completion Date :||July 2018|
Patient with cardiogenic shock table defined by the combination of a low cardiac output even as the filling pressures are normal or high, originally of hypoperfusion and organ suffering.
- Mortality at day 30 [ Time Frame: 30 days ]Death rate at 30 days of follow-up
- Analysis of mortality at day 30 by subgroup on age, sex, NYHA grade, initial etiology [ Time Frame: 30 days ]Rate of mortality at day 30 distributed by subgroup on age, sex, NYHA grade, initial etiology (Including ischemic versus non-ischemic heart disease, type and assistance and medical treatment)
- Mortality at 1 year [ Time Frame: 1 year ]Death rate at 1 year of follow-up
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02703038
|Toulouse, France, 31059|
|Principal Investigator:||Clément DELMAS||AP|